- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- IgAN
- Events
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefR
- Radiology Toolkit
- On Demand Webinars
- Infographics
- Podcasts
- Videos
- Request a Presentation
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Biomarkers In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
About This Event
Biomarkers In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Background
Clinical complications associated with autosomal polycystic kidney disease (ADPKD) appear gradually over time and are associated with the progressive development of cysts, kidney enlargement, and loss of renal function.1 The clinical course of ADPKD is marked by a long course of stable kidney function, despite the relentless expansion of kidney volume due to the growth of cysts.1 Height adjusted total kidney volume (Ht-TKV) has been recognized as a prognostic biomarker of cyst burden and disease severity.2 Can biomarker data provide additional information to improve prognostication for patients with ADPKD? Is it possible to create a biomarker profile to phenotype patients with ADPKD?
Did You Know?- Tubular secretory clearance may be compromised before detectable changes in GFR in patients with ADPKD.3
- In this cutting-edge webinar, we will discuss the most current data on biomarkers in ADPKD, focusing on those that are most validated in the literature.
- The different types of biomarkers (i.e., urine, serum, etc.) and how they can be utilized to understand ADPKD progression
- Key biomarkers associated with prognostication and how these biomarkers might be used to evaluate ADPKD disease progression
- Current gaps in the literature and potential next steps for future research in ADPKD biomarkers will be discussed
- Halvorson CR et al. Int J Nephrol Renovasc Dis. 2010; 3: 69-83.
- Irazabal MV et al. JASN. 2015; 26: 160-172.
- Wang K et al. CJASN. 2020; 15: 80–88.
Featuring
Pranav Garimella, MBBS, MPH, FASN
Associate Professor of MedicineUniversity of California San Diego*
Dr Garimella is an Associate Professor of Clinical Medicine and Nephrology at UC San Diego. He is the Director of Acute Dialysis Services at UC San Diego Health and the founding Director of the UCSD PKD Center of Excellence. He received his training in India, Chicago, and completed his fellowship at Tufts University, training in clinical nephrology with a focus on polycystic kidney disease with Dr Ron Perrone. His research endeavors have led to multiple NIH-funded studies and numerous peer-reviewed publications on the topic of kidney diseases. He has an ongoing NIH grant for his research elucidating aspects of kidney disease and has been the recipient of a multitude of teaching and clinical excellence awards. He is also involved in initiatives to develop programs specifically targeted at minority populations in an effort to improve health literacy and potentially clinical outcomes
Kelly Reed, PhD
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Kelly Reed, PhD, joined Otsuka in 2012 and is currently a Senior Medical Science Liaison on our Nephrology East Team. Dr Reed has collaborated with several national professional organizations and healthcare systems providing educational presentations on hyponatremia and Autosomal Dominant Polycystic Kidney Disease (ADPKD). She has been a leader in resource development for the MSL team, co-led the nephrology MSL new hire training program during expansion and served as a mentor to several MSL new hires. Dr Reed earned her doctorate from Virginia Commonwealth University in Richmond, Virginia and completed her clinical internship at the Mailman Center for Child Development in Miami, Florida, followed by a two year fellowship at Cincinnati Children’s Hospital Medical Center.
Marla Dallal, PharmD, RPH
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.
*Dr Garimella is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Reed and Dallal are employees of OPDC.
If you would like to register for the 3:00 pm to 4:00 pm EDT broadcast, please click below:
Registration
Related Resources
Related Events
-
Cooking Demo: Dietary Considerations for Patients with IgA Nephropathy
March 12, 2025 from 12:00 pm to 1:00 pm
Join Today for Instant Access to all NephU Offerings.
Membership is free!
Join NephU today at no cost to register for this event and access to other premium content.
- The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
- Quickly learn more about the topics that interest you.
- Access our library of on-demand kidney health resources
- Gain key insights from industry experts & though leaders.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.